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Effects of Environmental Oxidant
Stressors on Individuals with a G-6-PD
Deficiency with Particular Reference to
an Animal Model
by Edward J. Calabrese,* Gary Moore,*
and Regina Brown*
Individuals with a G-6-PD deficiency have long been known to be at increased risk to experience acute
hemolysis following exposure to elevated levels of certain oxidant drugs and industrial chemicals. How-
ever, the recognition ofenhanced susceptibility toenvironmental (or ambient) pollutants has generally not
beenconsidered. Recenttheoretical studies have suggested thatelevated levelsofambient ozone may be an
etiologic factor in the onset of acute hemolysis in the G-6-PD deficient individual. Furthermore, the
proposed usage ofeither chloramines or chlorine dioxide as replacements for chlorine for the disinfection
of drinking water should be investigated with respect to their potential adverse effects of individuals at
increased risk to oxidant stressors. In order to test these theoretical associations, two mouse strains, one
with low and the other with high levels ofG--PD activity in their red blood cells are being investigated to
determine if they simulate human G-6-PD deficient and normal individuals, respectively. Preliminary
results indicate that the mouse strain with low G-6-PD activity is markedly more susceptible to sodium
chlorite than mice of the high G-6-PD strain. This differential susceptibility to sodium chlorite toxicity
between the high and low G--PD. mouse strains suggests that further research designed to validate the
efficacy of this mouse model as a predictor of the human situation is warranted.
Introduction
Individuals with low levels of glucose-6-
phosphate dehydrogenase (G-6-PD) in their red
blood cells have long been known to be at increased
risk to experience hemolytic anemia following ex-
posure to certain oxidant drugs and industrial
chemicals (1-7). Over the years considerable prog-
ress has been made in identifying the nature of the
biochemical defect, its genetic basis, as well as its
distribution within the general population (8).
Today, G-6-PD deficiency is known to be a sex-
linked trait which is found quite frequently within
American black males, certain groups ofMediterra-
nean origin, and others as seen in Table 1 (1, 5, 8, 9).
Since the early 1960's considerable attention has
focused on the special hemolytic sensitivity of
* Division of Public Health, University of Massachusetts,
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G-6-PD deficient individuals to industrial chemicals
(1-7). Table 2 lists some common substances in-
cluding certain industrial chemicals which may
cause an abnormal degree of hemolysis in G-6-PD-
deficient workers. This list of hemolytic chemicals
includes general dye intermediates, the aromatic
amino and nitro compounds, as well as a number of
common household and prescription drugs (10-12).
Thus, the recognition of increased susceptibility
to hemolytic agents in industrial settings has been
well known for many years and has had at least
some limited application to occupational health
policies and practices (7, 10). In contrast, the rec-
ognition of enhanced susceptibility to environmen-
tal (or ambient) pollutants has generally been over-
looked (13).
The intention of this paper is to identify several
oxidant chemicals present in ambient air and certain
drinking water sources which may cause individuals
with a G-6-PD deficiency to be at increased risk
April 1979 49Table 1. Racial incidence of G-6-PD deficiency in males.
Incidence,
Race % Reference
American Negro 11 Beutler (8)
Caucasians
Americans 0.1 Stokinger and
British 0.1 Mountain (5)
Greeks 1-2 Lazarow (9)
Sardinians 1-8 Jensen (1)
Indians 0.3
Mediterranean Jews 11
European Jews 1
Mongolian
Chinese 2.5 Stokinger and Mountain (5)
Filipinos 12-13 Jensen (I)
Table 2. Partial list ofpotentially hemolytic chemicals and drugs.a
Acetanilid
Amyl nitrite
Aniline
Arsenic trioxide
Arsine
Benzene
Benzidine
Carbon tetrachloride
Chlorate
Chlorobenzene
Chloronitrobenzene
Chloroprene monomer
Cresol
Dinitrobenzene
Dinitrotoluene
Guaiacol
Hydroquinone
Hydroxylamine
Lead
Lead arsenate
Methycellosolve
Naphthalene
Naphthol
Nitric oxide
Nitrites
Nitrosamines
p-dichlorobenzene
p-nitrochlorobenzene
p-phenylenediamine
Phenylhydrazine
Phosphorus
Pyrocatechol
Selenium dioxide
Sulfonamides
Tetrachloroethane
Toluidine
Toluylenediamine
Trinitrotoluene
Raised oxygen pressure
Numerous N-containing drugs
a Data of Stokinger and Mountain (6).
with regard to the onset ofhemolysis relative to the
general population. The theoretical foundations
upon which this increased susceptibility is based
will be briefly summarized. Finally, preliminary
data will be presented concerning the development
of a potentially appropriate animal model for toxi-
cological studies which may simulate the responses
of the G-6-PD deficient human.
Ozone
In 1977 Calabrese et al. (14) published a theoreti-
cal study suggesting that G-6-PD deficient individu-
als would be at increased risk to developing acute
hemolytic anemia following prolonged exposure to
ozone at levels of approximately 0.5 ppm. This
hypothesis was based on the following information.
Exposure of humans to ozone stimulates the
hexose monophosphate pathway (HMP) including
the activity of G-6-PD within normal red blood
cells. Since the prime function of the HMP is to
provide sufficient reduced glutathione (GSH) to
protect the stability of the cell membrane, this re-
sponse is clearly adaptive and suggestive of oxida-
tive stress on the membrane.
Figure 1 represents the theoretical effects of
ozone on human red blood cells deficient in G-6-PD.
The vertical axis represents GSH levels in mg%o.
Normal individuals not under stress have GSH
levels ranging from 53 to 84 mgo (15), while G-6-PD
deficient individuals under similar nonstress condi-
tions have approximately 70o the GSH of normal
individuals with a range of38 to 51 mg% (16). When
testing for the occurrence of a G-6-PD deficiency
the individual is often given a GSH stability test. If
the individual does not have a deficiency, under the
stress conditions the GSH levels will often decrease
by approximately 20% before stabilizing. The rea-
son for GSH levels stabilizing is that the red blood
cells adapt to the chemical stress by increasing the
activity of the HMP including G-6-PD activity (17).
In contrast, there is a marked inability of the
G-6-PD deficient red blood cell to adapt to such
stresses in the GSH stability test with GSH levels
decreasing by 80-100% or a differential susceptibil-
ity ofat least fourtimes that ofnormal individuals at
that level of stressor agent (14, 16, 17). Numerous
studies have verified this differential susceptibility.
For example, Kosomer et al. (18, 19) noted that
GSH is rapidly regenerated in normal red blood
cells treated with various GSH oxidizing agents.
However, they also noted that the red blood cells of
G-6-PD-deficient individuals regenerated little, if
any, GSH under the same conditions.
In other studies, Buckley et al. (20) exposed nor-
mal individuals to 0.5 ppm ozone fornearly 3 hr and
noted a 14% reduction in GSH levels. These sub-
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FIGURE 1. Theoretical effects of ozone on human red blood cells
deficient in G-6-PD.
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oxidant stress by increasing the activity of G-6-PD
by 20o. Such a response would help to stabilize
GSH levels. It should be emphasized that such
adaptive capabilities are significantly reduced in the
G-6-PD-deficient person. The question emerges as
to how much of a decrease in GSH levels would
have occurred under similar ozone exposure in a
G-6-PD deficient individual. Unfortunately, we do
not know. However, if one assumes that G-6-PD-
deficient individuals are at increased risk to ozone,
as the data ofBuckley et al. suggest, and ifone also
assumes that G-6-PD deficient individuals are four
times as susceptible to ozone-induced hematologi-
cal changes when GSH levels in normals are de-
creased by approximately 20%o as based on the pre-
vious model involving GSH stability tests, then one
can calculate the theoretical effects of ozone on in-
dividuals with a G-6-PD deficiency.
It therefore follows that the 14% decrease in GSH
levels in normal persons following exposure to 0.5
ppm ozone for approximately 3 hr would be ap-
proximately equal to 56% reduction in GSH levels
in deficient individuals (14). Thus, a G-6-PD-
deficient individual with a typical GSH of 40 mgo
and with similar ozone exposure would be predicted
to have its GSH level decreased to 18 mg%o. Since
GSH levels below 20 mg%o in the GSH stability test
are usually associated with the occurrence of
hemolysis it is suggested that such an ozone expo-
sure in G-6-PD deficient people will be associated
with the precipitation of acute hemolysis (14).
It is not suggested that one should adhere rigor-
ously to proposed quantitative association just put
forth because ofthe magnitude of the assumptions.
However, the well established differential suscepti-
bility ofG-6-PD-deficient and normal individuals to
oxidant stresses, especially in light of the data of
Buckley et al. (20), clearly suggests the G-6-PD-
deficient individuals are predisposed to developing
increased hemolytic sensitivity following levels of
ozone commonly encountered in various regions of
the country. In light ofthe high incidence ofG-6-PD
deficiency within American black males and the oc-
currence of elevated ozone in many of our urban
areas, there is a critical need to evaluate the
hypothesis that G-6-PD deficients are at increased
risk to ozone induced hemolysis.
Oxidants in Drinking Water
One ofthe areas ofhighest priority within EPA in
the past several years has been identification of
chlorinated hydrocarbon products ofchlorination in
drinking water and estimation oftheir carcinogenic
potential. In fact, EPA has recently issued a direc-
tive to communities with water sources serving
greater than 75,000 people to initiate activated car-
bon treatment of drinking water so that
trihalomethane levels may be significantly reduced
(21). However, the use of activated carbon in
smaller plants is considerably more expensive,
often by greater than a factor of 10 (22). Con-
sequently, EPA is actively investigating alternate
forms of chemical disinfection to replace chlorine.
The possible replacement must be easily generated,
be a good biocide, provide a residual, have less un-
desirable by-products than free chlorine, and be
cost-effective. Two of the potential alternatives
considered include chloramines and chlorine
dioxide (C102) (23).
Chloramines
Despite its potential as a disinfectant for potable
water, concern has emerged that ingestion of
chloramines via water may be a cause ofhemolytic
anemia in certain segments of the population. For
instance, chloramines from drinking water have
been identified as the causative agent responsible
for the occurrence of acute hemolytic anemia in
dialyzed anemic patients (24, 25). Chloramines act
in such a way as to cause not only direct oxidant
stress to red cell membranes but also inhibit the
HMP. By reducing the ability ofred cells to adapt to
oxidant stress, chloramine exposure may potentiate
the inherent defect of HMP metabolism in uremic
individuals.
It was further suggested that all uremic patients
be checked for G-6-PD activity prior to dialysis
treatment (24, 25). It is difficult to define accurately
the risk ofacute hemolysis in G-6-PD deficient indi-
viduals who consume water treated with chlor-
amines based on the dialysis studies. While it is
clear that during hemodialysis small volumes of
blood are exposed to large volumes ofdialysis fluid,
it is equally clear that chloramines inhibit the activ-
ity ofthe HMP and would therefore further reduce
the already diminished activity of G-6-PD in defi-
cient individuals.
Chlorine Dioxide
With respect to disinfection treatment of surface
waters with C102, two of the primary products re-
sulting from such treatment include chlorates (26)
and chlorite (26, 27), with chlorite appearing in con-
centrations of up to 50%o of the C102 demand.
The oral administration of large doses chlorates
has been shown to produce methemoglobinemia (28,
29) with blood destruction and nephritis in acute
poisoning (28). Richardson (28) suggested that
April 1979 51similar changes might develop in chronic poisoning
with manifestations of anemia, uremia, and evi-
dence of nephritis.
Chlorite and hypochlorite are thought to oxidize
hemoglobin more rapidly than chlorate (30) and may
even be involved in the formation of MetHb by
chlorate (31). Further, since chlorite is a powerful
producer of MetHb, Musil et al. (32) recommended
that water for consumption contain no chlorite (0.0
mg/l.), since it might prove toxic to neonates. It is
on the basis ofthis work that the Norwegian Health
Authority recommends a residual chlorite concen-
tration of0.0 mg/l. in potable water supplies.
Although it is not known if individuals with a
G-6-PD deficiency would be at increased risk to the
adverse effects of chlorate or chlorite, especially
their methemoglobinizing effects, there is evidence
that the NADH content of G-6-PD-deficient eryth-
rocytes may be decreased (33, 34), and this may
result in a diminished rate of MetHb reduction by
the NADH-linked pathway (35). Additionally, a re-
duced GSH level may compromise the ability ofthe
G-6-PD deficient cell to reduce the oxidant directly
by GSH which is thought to be one of the initial
responses of cells to oxidant stress (36).
Copper
Copper is another substance that has been shown
to inhibit the HMP, and considerable information
has slowly emerged over the last 50 years which
indicates that elevated copper levels in red cells
may precipitate the onset of acute hemolysis. Cop-
per may oxidize reduced GSH as well as inhibit the
activity of G-6-PD and GSH reductase. The inhibi-
tion ofthe activity ofeach ofthese enzymes would
result in lowered GSH levels and makes the red cell
membrane more susceptible to oxidant stress (37).
Although these previous biochemical studies of
copper toxicity utilized very high levels of copper,
Boulard et al. (37) have revealed that even nearly
physiological levels ofcopper markedly inhibited a
variety of important red cell enzymes including
G-6-PD, pyruvate kinase, 6-phosphogluconate de-
hydrogenase and others.
Thus, it was speculated by Beutler and his as-
sociates (37) that many "apparent" enzymatic de-
fects ofthe red cell may result from inhibition ofred
cell enzymes by elevated serum copperlevels which
are frequently found in patients with various
chronic disorders.
The question of course emerges as to whether
elevated levels ofcopper in drinking water may ac-
tually be a causative agent in hemolysis? Various
reports (38-40) have noted that elevated copper
levels (500-800 ppb or 0.5-0.8 ppm) in dialysis fluid
have resulted in acute hemolysis in non-G-6-PD
deficient patients in similar fashion to the
chloramines. Additionally, in areas where raw wa-
ters have a markedly alkaline or acid pH and copper
plumbing is utilized to convey water to the artificial
kidney without processing with deionizing ap-
paratus to remove the copper, chronic intoxication
could result.
With regard to nondialyzed individuals with a
G-6-PD deficiency, what is the risk from elevated
copper in the drinking water? Although present
studies do not provide sufficient data to make any
definite conclusions, it is known that low levels of
copper can markedly reduce the activity of the
HMP including the G-6-PD activity; that exposure
to copper in drinking water at levels in excess of I
ppm can lead to elevated levels ofcopper in tissues
(41); that levels of copper exceeding 1 ppm are not
uncommon in areas where the water is corrosive
and the households use copper piping (42); and that
when copper levels in water equal or exceed 1 ppm,
the contribution ofcopper from water may equal or
exceed that normally obtained from food. Thus,
there is a reasonable likelihood that exposure to
copper from community drinking water may offer
an important health hazard to those with a G-6-PD
deficiency.
This suggestion was recently supported by the
National Academy of Sciences publication on
Drinking Water and Health (43) which suggests that
those with a G-6-PD deficiency may be at increased
risk to elevated levels ofcopper. It is interesting to
note that sheep which have exceptionally low levels
ofG-6-PD activity in their red cells are known to be
highly sensitive to acute hemolysis following ele-
vated copper exposure (43).
Animal Model
Although a large body of evidence is available
concerning the increased susceptibility of G-6-PD
deficient individuals to numerous oxidant drugs and
industrial chemicals there is a lack of animal and
human data concerning their susceptibility to the
environmental oxidants previously mentioned. It is
therefore extremely important to develop a reliable
animal model which may simulate the human con-
dition whereby multiple interactions may be tested.
At the University of Massachusetts we are in the
process of evaluating the efficiency of a mouse
model as a simulator ofthe human G-6-PD-deficient
experience.
Hutton (44) has previously reported that genetic
regulation of G-6-PD activity in 16 inbred mouse
strains falls into three distinct classes: high (i.e.,
"'normal"), intermediate, and low. That ratios of
Environmental Health Perspectives 52G-6-PD activity in circulating red blood cells of the
three activity classes are 3:2:1 (45). Consequently, a
low G-6-PD mouse strain has approximately 33% of
the G-6-PD activity in its red blood cells as com-
pared to the normal G-6-PD strain. The level of
G-6-PD activity in human individuals characterized
as "deficient" (i.e., Negroes with A-variant; this is
the most common G-6-PD deficient variant) may
range from 8 to 20% that ofthe normal (8). Thus, the
mouse strain selected here is very comparable to
that of the human A-variant with regard to relative
deficiency levels. It is also important to note that
the mouse G-6-PD enzyme is identical to the A-
variant G-6-PD with regard to optimal pH activity,
thermal stability and Michaelis constants for
G-6-PD and NADP. Further, the activity units in
normal individuals as measured by millimoles of
NADP reduced is 14.2-22.0 units, while the G-6-PD
activity level in the normal mouse class is 15-17
units (3, 46). Additionally, the levels of G-6-PD in
mouse red blood cells decreases with cellular age in
similar fashion as in man (8). Therefore, in both
relative and absolute comparisons, G-6-PD in the
mouse strain and human A-strain is very similar.
It is interesting to note that in GSH stability tests
between the strains performed on a limited number
of mice by Hutton (44) the low G-6-PD strain was
somewhat more sensitive than the normal (i.e.,
high) strain. However, the increased sensitivity was
not nearly as great as in the human situation, possi-
bly because of the higher G-6-PD levels in the low
activity mouse strain relative to the human G-6-PD
deficient condition. Since G-6-PD activity in the low
mouse strain are somewhat higher than G-6-PD
levels in the human A-variant and especially higher
than the mediterranean variant which has a G-6-PD
activity of only 1-7% of normal (8), it may be rea-
sonably assumed that the model may infact result in
a high incidence of false negatives.
Our laboratory has been developing experience
with these potential animal models, and some of our
preliminary results are provided in Table 3. Table 3
represents a comparison of hematological parame-
ters between mouse strains with high (A/J) and low
(C57L/J) G-6-PD activity. The C57L/J strain has
approximately 28% ofthe G-6-PD activity and 83%
of the GSH levels of the A/J strain, respectively.
There are also marked differences in red blood cell
count and hematocrit values. Furthermore, there is
marked difference in osmotic fragility between the
two strains with C57L/J being more susceptible.
Figure 2 presents a summary ofour recent studies
which have revealed that the low G-6-PD strain is
more susceptible to oxidant stress in the form of
elevated doses of sodium chlorite with regard to
various hematological parameters ofpotential clini-
cal significance including red blood cell count,
hemoglobin levels, hematocrit, and reticulocytes.
The values represent the percent increase or de-
crease from baseline values previously presented in
Table 3.
Conclusions
Although there is a long history of recognition
that G-6-PD-deficient individuals are at increased
risk to the development of hemolytic anemia fol-
lowing exposure to elevated amounts of certain
oxidant drugs and industrial chemicals, very little
attention has been given to quantifying the risk as-
sessment of such individuals to environmental pol-
lutants despite the theoretical basis that they may
be at increased risk. Furthermore, since oxidant
stressors such as chlorine dioxide, and chloramines
are being considered as possible replacements for
chlorine in smaller communities, their effects on
potential high risk groups must be evaluated. Fi-
nally, there is an animal model which is currently
Table 3. Comparison of hematologic parameters of mouse strains with high (A/J) and low (C57L/J) G-6-PD activity.
Low-activity strain High-activity strain
C57LJJ A/J
Standard Number of
Hematologic deviation mice
parameters Mean (SD) (N) Mean SD (N)
G-6-PD (IV)/g hemoglobin/ 100 ml whole blood 2.30 0.36 38 7.83 0.95 40
Red blood cell (RBC) count (x 106) 7.58 0.55 38 6.52 0.56 40
Hemoglobin (HGB) g/dl 13.67 0.82 38 12.27 1.09 40
Hematocrit (HCT), % 35.84 2.76 32 30.09 2.56 32
Mean corpuscular volume (MCV), p3 47.70 1.48 32 46.83 1.05 32
Mean corpuscular hemoglobin (MCH), ,,uug 18.21 0.59 38 18.96 0.73 40
Methemoglobin (MeTHB), % 1.09 0.83 20 1.07 0.94 19
Reticulocytes (Retic), % 2.90 1.03 22 3.13 0.88 24
Glutathione (GSH), mg%o 68.09 16.16 14 82.10 11.78 10
Osmotic fragility
(% hemolysis at 0.55 tonicity) 29.68 9.18 22 20.56 7.61 18
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FIGURE 2. Comparison of changes in hematological parameters
(red blood cells, hemoglobin, hematocrit, reticulocytes) in
mice with low and high G-6-PD activity following in vivo
exposure to sodium chloride: (O) low G-6-PD strain (C57VJ);
(O) high G-6-PD strain (A/J).
being evaluated for its accuracy in simulating the
human deficient condition. Preliminary findings
suggest that this model may offer the opportunity to
predict the possible differential susceptibility of
G-6-PD deficients and normal individuals to various
types of oxidant stressors.
Future studies will involve the establishment of
dose-time-effect relationships with chlorite and
other potential environmental oxidants as well as
more precise analyses of how the red cells of the
two strains attempt to adapt to exogenous oxidant
stresses. Also, comparisons of responses in the
model strains to oxidant stressors which have well
established responses in normal and G-6-PD-
deficient humans will help establish the degree of
direct comparability between the animal and the
human condition.
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